These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

997 related articles for article (PubMed ID: 23423920)

  • 1. Coregistered whole body magnetic resonance imaging-positron emission tomography (MRI-PET) versus PET-computed tomography plus brain MRI in staging resectable lung cancer: comparisons of clinical effectiveness in a randomized trial.
    Yi CA; Lee KS; Lee HY; Kim S; Kwon OJ; Kim H; Choi JY; Kim BT; Hwang HS; Shim YM
    Cancer; 2013 May; 119(10):1784-91. PubMed ID: 23423920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positron emission tomography in staging early lung cancer: a randomized trial.
    Maziak DE; Darling GE; Inculet RI; Gulenchyn KY; Driedger AA; Ung YC; Miller JD; Gu CS; Cline KJ; Evans WK; Levine MN
    Ann Intern Med; 2009 Aug; 151(4):221-8, W-48. PubMed ID: 19581636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative staging of non-small-cell lung cancer: comparison of whole-body diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography.
    Sommer G; Wiese M; Winter L; Lenz C; Klarhöfer M; Forrer F; Lardinois D; Bremerich J
    Eur Radiol; 2012 Dec; 22(12):2859-67. PubMed ID: 22772365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coregistered whole body magnetic resonance imaging-positron emission tomography (MRI-PET) versus PET-computed tomography plus brain MRI in staging resectable lung cancer.
    Parry PV; Engh JA
    Neurosurgery; 2013 Dec; 73(6):N11-3. PubMed ID: 24257336
    [No Abstract]   [Full Text] [Related]  

  • 5. Positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced nonsmall cell lung cancer--initial results.
    Plathow C; Aschoff P; Lichy MP; Eschmann S; Hehr T; Brink I; Claussen CD; Pfannenberg C; Schlemmer HP
    Invest Radiol; 2008 May; 43(5):290-7. PubMed ID: 18424949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic Performance of Whole-Body Diffusion-Weighted Imaging Compared to PET-CT Plus Brain MRI in Staging Clinically Resectable Lung Cancer.
    Usuda K; Sagawa M; Maeda S; Motono N; Tanaka M; Machida Y; Matoba TM; Watanabe N; Tonami H; Ueda Y; Uramoto H
    Asian Pac J Cancer Prev; 2016; 17(6):2775-80. PubMed ID: 27356689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients.
    Wu Y; Li P; Zhang H; Shi Y; Wu H; Zhang J; Qian Y; Li C; Yang J
    Int J Cancer; 2013 Jan; 132(2):E37-47. PubMed ID: 22890912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis.
    Machado Medeiros T; Altmayer S; Watte G; Zanon M; Basso Dias A; Henz Concatto N; Hoefel Paes J; Mattiello R; de Souza Santos F; Mohammed TL; Verma N; Hochhegger B
    Eur Radiol; 2020 Jul; 30(7):3641-3649. PubMed ID: 32125513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging.
    Yi CA; Shin KM; Lee KS; Kim BT; Kim H; Kwon OJ; Choi JY; Chung MJ
    Radiology; 2008 Aug; 248(2):632-42. PubMed ID: 18552311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is a selective brain (18)F-FDG PET/CT study profitable in patients with small cell lung cancer?
    Palomar Muñoz A; García Vicente AM; Bellón Guardia ME; González García B; Talavera Rubio MP; Pilkington Woll JP; Núñez García A; Poblete García VM; Cordero García JM; Soriano Castrejón A
    Rev Esp Med Nucl Imagen Mol; 2012; 31(3):124-9. PubMed ID: 21722995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.
    Billé A; Pelosi E; Skanjeti A; Arena V; Errico L; Borasio P; Mancini M; Ardissone F
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):440-5. PubMed ID: 19464906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for brain metastases in patients with stage III non-small cell lung cancer: Is there additive value of magnetic resonance imaging above a contrast-enhanced computed tomography of the brain?
    Hendriks LE; Bootsma GP; de Ruysscher DK; Scheppers NA; Hofman PA; Brans BT; Dingemans AM
    Lung Cancer; 2013 Jun; 80(3):293-7. PubMed ID: 23518381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-way Comparison of Whole-Body MR, Coregistered Whole-Body FDG PET/MR, and Integrated Whole-Body FDG PET/CT Imaging: TNM and Stage Assessment Capability for Non-Small Cell Lung Cancer Patients.
    Ohno Y; Koyama H; Yoshikawa T; Takenaka D; Seki S; Yui M; Yamagata H; Aoyagi K; Matsumoto S; Sugimura K
    Radiology; 2015 Jun; 275(3):849-61. PubMed ID: 25584709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial.
    Darling GE; Maziak DE; Inculet RI; Gulenchyn KY; Driedger AA; Ung YC; Gu CS; Kuruvilla MS; Cline KJ; Julian JA; Evans WK; Levine MN
    J Thorac Oncol; 2011 Aug; 6(8):1367-72. PubMed ID: 21587082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pure ground glass nodular adenocarcinomas: Are preoperative positron emission tomography/computed tomography and brain magnetic resonance imaging useful or necessary?
    Cho H; Lee HY; Kim J; Kim HK; Choi JY; Um SW; Lee KS
    J Thorac Cardiovasc Surg; 2015 Sep; 150(3):514-20. PubMed ID: 26189165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study].
    Margery J; Milleron B; Vaylet F; Grahek D; Lebeau B; Mangiapan G; Bonardel G; de Labriolle-Vaylet C; Meignan M; Carette MF; Talbot JN; Housset B
    Rev Pneumol Clin; 2010 Oct; 66(5):313-20. PubMed ID: 21087727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?
    Aquino SL; Fischman AJ
    Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole-Body MRI: Comparison of Its Capability for TNM Staging of Malignant Pleural Mesothelioma With That of Coregistered PET/MRI, Integrated FDG PET/CT, and Conventional Imaging.
    Ohno Y; Yui M; Aoyagi K; Kishida Y; Seki S; Koyama H; Yoshikawa T
    AJR Am J Roentgenol; 2019 Feb; 212(2):311-319. PubMed ID: 30512992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The additional value of FDG PET imaging for distinguishing N0 or N1 from N2 stage in preoperative staging of non-small cell lung cancer in region where the prevalence of inflammatory lung disease is high.
    Turkmen C; Sonmezoglu K; Toker A; Yilmazbayhan D; Dilege S; Halac M; Erelel M; Ece T; Mudun A
    Clin Nucl Med; 2007 Aug; 32(8):607-12. PubMed ID: 17667432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.